Evercyte GmbH
Otto Kanzler is a highly experienced CEO with a background in biotechnology and pharmaceuticals. Currently serving as the CEO of Rockfish Bio AG, InnoFly BioCenter GmbH, Evercyte GmbH, Innofly Management GmbH, TAmiRNA GmbH, and Chorus GmbH, Otto has a proven track record of leading successful companies in the field. With a career that spans over two decades, including their previous role as Head of Planning and Co-ordination at Boehringer Ingelheim, Otto has a wealth of knowledge and expertise in strategic planning, business development, and technology consulting within the industry.
This person is not in any teams
This person is not in any offices
Evercyte GmbH
Evercyte - the pharmacocellomicsTM company. Vision Acceleration of drug finding and development by reduction of development time and cost by introducing panels of immortalized human cell strains for drug screening strategies. Evercyte will establish the new concept of “pharmacocellomicsTM” in the field of pre-clinical developments. Therefore, we will provide primary cells from different patients and tissues that are immortalized by telomerase or other strategies (SV40; SNEV) that we have established. Thus we guarantee cell strains with the most similar phenotype to the primary cells in sufficient amounts to perform reproducible preclinical drug testing. We will deliver (i) single immortalized cell strains including mesenchymal stem cells that can be differentiated to the cell type of interest; (ii) cell panels including sufficient cell strains of different tissues and/or donors of different status (healthy, diseased, young, old, etc) in order to generate statistically meaningful data that allow to estimate drug efficiencies and toxicity with high predictive power. Finally, (iii) we will establish customer-tailored immortalized cell strains according to the needs of specific customers.